Nuvisertib received FDA fast track designation for myelofibrosis, showing significant clinical activity in symptom and spleen response, and improvements in bone marrow fibrosis, hemoglobin, and ...

Please provide your email address to receive an email when new articles are posted on . Rusfertide reduced need for phlebotomies and offered better hematocrit control than placebo. Results showed ...

In this fourth part of a discussion with The American Journal of Managed Care®, Andrew Kuykendall, MD, clinical researcher at Moffitt Cancer Center and VERIFY investigator, speaks to the impressive ...

Ruxolitinib improves hematocrit control and treatment response in polycythemia vera compared to best available therapy. Patients on ruxolitinib show better Myeloproliferative Neoplasms-Symptom ...

Dr. Aaron Gerds explained when treatment with rusfertide will become accessible for patients with a myeloproliferative neoplasm like polycythemia vera. Dr. Aaron Gerds sat down for an interview with ...

The risk of venous and arterial thrombosis in polycythemia vera patients with secondary malignancies. Temporal trends in myeloproliferative neoplasms–related mortality in the United States over the ...

While taking testosterone-based HRT, your doctor will monitor your bloodwork for signs of polycythemia. If found, several treatment options are available. Testosterone is responsible for many body ...

Rusfertide, an investigational, first-in-class, self-injected peptide targeting the hepcidin pathway, shows efficacy in significantly reducing the need for phlebotomy in patients with polycythemia ...

Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall Street, and biotechnology. He is also a co-host of the weekly biotech podcast ...

CHICAGO -- The use of the investigational weekly subcutaneous injection rusfertide significantly reduced the need for phlebotomy among polycythemia vera patients who had been dependent on it, the ...